Patents by Inventor John Emmerson CAMPBELL

John Emmerson CAMPBELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,4-pyridone bicycic heteroaryl compounds
    Patent number: 10150759
    Abstract: The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 11, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, John Emmerson Campbell
  • Substituted benzene compounds
    Patent number: 10098888
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 16, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki
  • Substituted benzene compounds
    Patent number: 10092572
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: October 9, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • Multicyclic compounds and methods of use thereof
    Patent number: 10085968
    Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 2, 2018
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC.
    Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180258104
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20180208591
    Abstract: The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 1, 2017
    Publication date: July 26, 2018
    Inventors: John Emmerson CAMPBELL, Kevin W. KUNTZ
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 9994590
    Abstract: Provided herein are substituted [1,2,4]triazlolo[1,5-?]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 12, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20180134692
    Abstract: The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: June 16, 2017
    Publication date: May 17, 2018
    Inventors: Kevin W. KUNTZ, John Emmerson CAMPBELL
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180118727
    Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson CAMPBELL, Una CAMPBELL, Taleen G. HANANIA, Liming SHAO
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180072759
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Inventors: John Emmerson Campbell, Philip Wendell Jones, Michael Charles Hewitt
  • SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20180065954
    Abstract: The present invention relates to substituted bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: April 14, 2017
    Publication date: March 8, 2018
    Inventor: John Emmerson Campbell
  • SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS
    Publication number: 20180037590
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Xinhe Jones, Linghong Xie
  • Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
    Patent number: 9856274
    Abstract: Provided herein are substituted pyrazolopyridine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 2, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
    Publication number: 20170355712
    Abstract: The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: May 22, 2017
    Publication date: December 14, 2017
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Megan Alene Foley, Darren Martin Harvey, Kevin Wayne Kuntz, James Edward John Mills, Michael John Munchhof
  • Substituted quinolines as PDE-10 inhibitors
    Patent number: 9834564
    Abstract: Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
  • SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20170290837
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: November 22, 2016
    Publication date: October 12, 2017
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki
  • ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
    Publication number: 20170291905
    Abstract: Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: Epizyme, Inc.
    Inventors: Richard Chesworth, Lorna Helen Mitchell, John Emmerson Campbell, Lawrence Alan Reiter, Kerren Kalai Swinger
  • HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170291890
    Abstract: The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Inventor: John Emmerson Campbell
  • Substituted 6,5-fused bicyclic heteroaryl compounds
    Patent number: 9776996
    Abstract: The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 3, 2017
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kevin Wayne Kuntz
  • SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20170217941
    Abstract: The present invention relates to substituted benzene compounds and bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: June 25, 2015
    Publication date: August 3, 2017
    Inventor: John Emmerson CAMPBELL